Context
CMN has become the leading private practice dedicated to nuclear medicine in France through creation and acquisitions of centers
In order to strengthen the nuclear medicine specialty and make it more accessible, CMN has designed an impactful medical project with a strong focus on innovation, quality and accessibility of care
Operating four centers in the Paris region and about to open the first private nuclear medicine center in Paris, the shareholders were keen to benefit from their first-mover advantage to partner with a private equity fund to help them accelerating the development of the company
After a competitive process, the eight physicians shareholders have decided to team up with MBO & Co and will retain the majority of the capital
This fundraising will then allow CMN to pursue an ambitious medical project to provide patients with easier access to nuclear medicine throughout France, while ensuring a consistent quality of service and care.
About CMN
CMN was founded in 1994 by two physicians shareholders with the first center located in Pontault-Combault (77).
Today, the company is the leading private practice dedicated to nuclear medicine in France own by 8 physicians shareholders. CMN has four centers in the Paris region (Champigny sur Marne, Meaux, Melun and Jossigny) and diagnosed over 35,000 patients in 2021.
Additionally, CMN will operate in 2022 the first private nuclear medicine center in Paris, within the Hôpital Privé des Peupliers, to meet the high demand from physicians and patients.
About MBO & Co
MBO & Co manages €750 million dedicated to capital investment in SMEs and intermediate-sized enterprises valued between €20 million and €150 million and invests in ambitious development and transformation projects, arising from transmission operations or to strengthen the company’s capital.
MBO & Co partners with committed entrepreneurs, to whom it provides strategic guidance, operational efficiency, and organizational improvement, with the common goal of combining sustainable growth and long-term optimization of value creation.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co
Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co
Bryan, Garnier & Co led a highly competitive process involving numerous financial sponsors and advised CMN to select the best partner to support its growth
We initially assisted our client on its strategy to build the group in the future
A tailor-made process was designed to educate PE firms in order to introduce them to the nuclear medicine sector, a new specific market segment distinct from the other medical imaging activities
As a result of absolute commitment of its team and a demanding process management, Bryan Garnier & Co delivered on all objectives
This transaction continues to demonstrate Bryan, Garnier & Co expertise and track-record within healthcare services
Share